National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 30060 [2021-11711]
Download as PDF
<![CDATA[
30060
Federal Register / Vol. 86, No. 106 / Friday, June 4, 2021 / Notices
regarding information needed by
Campaign audiences as well as their
attitudes and behaviors related to
COVID–19 and the COVID–19 vaccines.
These will be used to inform the
development of Campaign messages and
strategy.
Copy Testing Surveys
Prior to placing Campaign
advertisements in market, ASPA will
conduct copy testing surveys to ensure
the final Campaign messages have the
intended effect on target attitudes and
behaviors. Copy testing surveys will be
conducted with sample members who
comprise the target audiences; these
surveys will assess perceived
effectiveness of the advertisements as
well as the effect of exposure to an ad
on key attitudes and behavioral
intentions. The results from these
surveys will be used internally by ASPA
to inform decisions on Campaign
messages and materials; for example, to
identify revisions to the materials or
determine which advertisement to move
to market.
Need and Proposed Use: In light of
the current COVID–19 crisis, this
information is needed given the impact
of the pandemic on the nation. The
Secretary of the Department of Health
and Human Services (HHS) has declared
a public health emergency effective
January 27, 2020, under section 319 of
the Public Health Service Act (42 U.S.C.
247d [1]) and renewed it continually
since its issuance (see links to the
determination here and here).
Additionally, in accordance with 5 CFR
1320.13, HHS previously requested
emergency submissions (sections 1320
(a)(2)(ii) and (2)(iii) of the federal
regulations.
ESTIMATED ANNUALIZED BURDEN HOUR TABLE
CET
Foundational
focus groups
Copy testing
survey
Hours to screen ...........................................................................................................................
Screening completes (per wave) .................................................................................................
Screening participants (total/screened out) .................................................................................
Hours to complete survey/group .................................................................................................
Participants (per wave/round) ......................................................................................................
Number of waves/rounds .............................................................................................................
Burden per wave/round ...............................................................................................................
N/A
N/A
N/A
0.12
1,000
92
120
.09
2,500
20,000/19,136
1.5
108
8
387
0.03
6,700
53,600/45,600
0.33
1,000
8
330
Total participants ..................................................................................................................
92,000
864
8,000
Total respondents * ...............................................................................................................
92,000
20,000
53,600
Total burden hours ...............................................................................................................
11,040
3,096
4,248
* Total respondents = total participants for each effort + total people screened out.
Sum of All Studies
Total Respondents: 165,600.
Total Burden Hours: 18,384.
Sherrette A. Funn,
Paperwork Reduction Act Reports Clearance
Officer, Office of the Secretary.
[FR Doc. 2021–11723 Filed 6–3–21; 8:45 am]
BILLING CODE 4150–25–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
VerDate Sep<11>2014
17:08 Jun 03, 2021
Jkt 253001
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Integrated Preclinical/
Clinical AIDS Vaccine Development Program
(IPCAVD) (U19 Clinical Trial Not Allowed).
Date: June 30, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G36,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Pegu, Ph.D.,
Scientific Review Officer, Scientific Review
Program, DEA/NIAID/NIH/DHHS, 5601
Fishers Lane, MSC–9823, Rockville, MD
20892, 240–292–0719, poonam.pegu@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
National Institutes of Health
Dated: May 28, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel; SARS-CoV–2, COVID–19
and Consequences of Alcohol Use (RFA AA
21–002, AA 21–003 and AA21–004).
Date: July 15–16, 2021.
Time: 9:00 a.m. to 6:00 p.m.
[FR Doc. 2021–11711 Filed 6–3–21; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
National Institute on Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
E:\FR\FM\04JNN1.SGM
04JNN1
]]>Agencies
[Federal Register Volume 86, Number 106 (Friday, June 4, 2021)]
[Notices]
[Page 30060]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-11711]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; Integrated Preclinical/Clinical
AIDS Vaccine Development Program (IPCAVD) (U19 Clinical Trial Not
Allowed).
Date: June 30, 2021.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G36,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Pegu, Ph.D., Scientific Review Officer,
Scientific Review Program, DEA/NIAID/NIH/DHHS, 5601 Fishers Lane,
MSC-9823, Rockville, MD 20892, 240-292-0719, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: May 28, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-11711 Filed 6-3-21; 8:45 am]
BILLING CODE 4140-01-P
